Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections | Zendy

Sarah C J Jorgensen | Zendy; Trang D Trinh | Zendy; Evan J. Zasowski | Zendy; Abdalhamid M Lagnf | Zendy; Samuel Simon | Zendy; Sahil Bhatia | Zendy; Sarah Melvin | Zendy; Molly E. Steed | Zendy; Natalie A. Finch | Zendy; Taylor Morrisette | Zendy; Sandy Estrada | Zendy; Joshua Rosenberg | Zendy; Susan L. Davis | Zendy; Michael J. Rybak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections

Author(s) -

Sarah C J Jorgensen,

Trang D Trinh,

Evan J. Zasowski,

Abdalhamid M Lagnf,

Samuel Simon,

Sahil Bhatia,

Sarah Melvin,

Molly E. Steed,

Natalie A. Finch,

Taylor Morrisette,

Sandy Estrada,

Joshua Rosenberg,

Susan L. Davis,

Michael J. Rybak

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02291-19

Subject(s) - gram negative bacterial infections , gram , medicine , gram negative bacteria , multiple drug resistance , tazobactam , microbiology and biotechnology , intensive care medicine , antibiotics , biology , antibiotic resistance , bacteria , escherichia coli , genetics , biochemistry , imipenem , gene

Our objective was to describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Gram-negative infections. This was a multicenter, retrospective, cohort study at eight U.S. medical centers (2015 to 2019). Inclusion criteria were age ≥18 years and receipt of C/T (≥72 hours) for suspected or confirmed MDR Gram-negative infection. The primary efficacy outcome, evaluated among patients with MDRPseudomonas aeruginosa infections, was composite clinical failure, namely, 30-day all-cause mortality, 30-day recurrence, and/or failure to resolve or improve infection signs or symptoms after C/T treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research